Condition: Hemodialysis · Sponsor: London Health Sciences Centre Research Institute
Cognitive decline is increasingly recognized among patients receiving maintenance hemodialysis (HD). This can include trouble remembering, slower thinking or mentally feeling foggy. This research is being done to determine if a new medication (AV-001) can protect the brain from injury caused by hemodialysis by strengthening blood vessels in the brain and reducing inflammation. If successful, this research could lead to better protection for the brains of people undergoing regular dialysis, potentially reducing the risk of cognitive decline and stroke.
This description comes directly from the study's public registry record.
Jarrin D Penny, PhD, RN · 519-685-8500 · jarrin.penny@lhsc.on.ca
Kathy Koyle · 519-685-8500 · kathleen.koyle@lhsc.on.ca
Always discuss trial participation with your own doctor first.
| London Health Sciences Centre | London, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07234890